thought leadership
Vax to the future: The resurgence of cancer vaccines and the challenges ahead
May 31, 2024
Cancer vaccines tailored to combat lethal tumors could transform the lives of patients across the globe. However, significant challenges are preventing these innovations from being realized. Our consultants explore why an agile and future-proofed commercialization strategy is needed to succeed in this complex landscape and ensure patients benefit from the potential of these life-saving therapies.
After a decade of limited success, scientists predict a turning point in research in cancer vaccines and development, captivating the industry and the public with renewed optimism regarding the potential to help patients resistant to conventional immunotherapies.
At this year’s American Association for Cancer Research (AACR) Annual Meeting in San Diego, the spotlight shone brightly on promising cancer vaccines, particularly personalized or individualized neoantigen therapies (INT). Numerous companies and academic institutions are advancing vaccines tailored to empower the immune system and combat even the most lethal tumors, with many presenting promising early data at the congress.
Despite the growing interest and resurgence in optimism, the pathway to the realization of cancer vaccines is complex, and faces many barriers. Capitalizing on the opportunity to deliver this life-changing therapy requires future-proofed planning that addresses a number of factors, including:
- Overcoming stigma
- Navigating the complex science
- Combination strategies
- Manufacturing and operations
- An uncertain landscape for policy access
Download the article to gain insights into the landscape for cancer vaccines, the challenges ahead, and how to ensure a successful commercial strategy.
Making the decisions that matter
Get in touch to learn how our global oncology experts can develop an agile and future-proofed commercialization strategy for your cancer vaccine.